These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2282861

  • 21. [Comparison of serum determinations of CA125, CA15-3 and CA50 in the preoperative evaluation of adnexal tumors].
    Gadducci A, Facchini V, Ferdeghini M, Ceccarini T, Bartolini T, Fontana V, Bianchi R, Fioretti P.
    Ann Ostet Ginecol Med Perinat; 1988; 109(4):199-204. PubMed ID: 3232907
    [No Abstract] [Full Text] [Related]

  • 22. Evaluation of serum sialic acid, heat stable alkaline phosphatase and fucose as markers of breast carcinoma.
    Patel PS, Baxi BR, Adhvaryu SG, Balar DB.
    Anticancer Res; 1990; 10(4):1071-4. PubMed ID: 2382978
    [Abstract] [Full Text] [Related]

  • 23. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J, Qian H, Tian Y.
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [Abstract] [Full Text] [Related]

  • 24. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
    Vardi JR, Tadros GH, Malhotra C, Charney T, Shebes M, Foemmel R.
    Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
    [Abstract] [Full Text] [Related]

  • 25. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S, Udagawa Y, Sasaki H, Ito K, Akiya K, Terashima Y, Takamizawa H, Ohkura H, Fujimoto S, Hashimoto M.
    Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
    Phocas I, Sarandakou A, Sikiotis K, Rizos D, Kalambokis D, Zourlas PA.
    Anticancer Res; 1996 May; 16(6B):3827-31. PubMed ID: 9042265
    [Abstract] [Full Text] [Related]

  • 31. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
    Kamiya N, Mizuno K, Kawai M, Kano T, Furuhashi Y, Tomoda Y.
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
    [Abstract] [Full Text] [Related]

  • 32. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M.
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [Abstract] [Full Text] [Related]

  • 33. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
    Nozawa S, Udagawa Y, Ito K, Susumu N, Sasaki H, Aoki D.
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
    [Abstract] [Full Text] [Related]

  • 34. The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma.
    Gadducci A, Ferdeghini M, Bartolini T, Facchini V, Mariani G, Bianchi R, Fioretti P.
    J Nucl Med Allied Sci; 1989 Feb; 33(3):243-6. PubMed ID: 2778499
    [Abstract] [Full Text] [Related]

  • 35. [Serum sialic acid bound to lipoproteins. Its contribution to the diagnosis and follow-up of melanoma].
    Sánchez Conejo-Mir J, Sotillo Gago I, Camacho F, Iglesias Huertas R.
    Med Cutan Ibero Lat Am; 1990 Feb; 18(4):219-23. PubMed ID: 2077306
    [Abstract] [Full Text] [Related]

  • 36. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P.
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [Abstract] [Full Text] [Related]

  • 37. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
    Suzuki M, Sekiguchi I, Tamada T.
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
    [Abstract] [Full Text] [Related]

  • 38. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
    Kimura E, Kobayashi S, Terashima Y.
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
    [Abstract] [Full Text] [Related]

  • 39. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
    Inal E, Laçin M, Asal K, Ceylan A, Köybaşioğlu A, Ileri F, Uslu SS.
    Kulak Burun Bogaz Ihtis Derg; 2004 Dec; 12(1-2):23-30. PubMed ID: 16010093
    [Abstract] [Full Text] [Related]

  • 40. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
    Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T.
    J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.